
Oncologist @SaintFrancisCancerCenter Heme-Onc Fellowship@UAMShealth | IM Board Certified | McLaren Flint-MSU IM Alumni | RMU Graduate | ๐ต๐ฐโน๐ฝโโ๏ธโฝ๏ธ๐
Tulsa, OK
Joined July 2020
- Tweets124
- Following239
- Followers229
- Likes386
Abdul Rafae retweeted
How I treat plasma cell leukemia @BloodPortfolio #mmsm @utswcancer @UTSWMedCenter @UAMSMyeloma @ldandersonjr @HadidiSamer @ASH_hematology
โก๏ธashpublications.org/blood/arโฆ
๐งต
Abdul Rafae retweeted
Day 3 #ASCO26 5 plenary highlights:
1. #PROTEUS: PeriOp/PostOp Apa in Prostate Ca
2. #SARC041: Adj Abema in dediff liposarcoma
3. #LIBRETTO432 : Adj Selpercatinib in NSCLC
4. #HARMONi6: 1L Ivonescimab in Sq mNSCLC
5. #RASolute302: 2L Daraxonrasib in Panc Ca
@ASCO
1/6
Abdul Rafae retweeted
I put together a free guide on using AI the right way in medicine. How to use it as a teacher. Where the ethical line is. 45+ research databases. Formal AI courses from AMA, AAMC, Harvard, Stanford. For medical students, IMGs, residents, and fellows:
linkedin.com/posts/faiz-anweโฆ
Abdul Rafae retweeted
JUST IN: The report we always look for every year: CANCER STATISTICS, 2026
New milestone with 5y Survival of 70%!!! Still a lot of room to improve but also excellent progress !
@AmericanCancer @CACancerJournal @DanaFarber
acsjournals.onlinelibrary.wiโฆ
Abdul Rafae retweeted
Treatment of Multiple Myeloma: ASCOโOntario Health (Cancer Care Ontario) Living Guideline | Journal of Clinical Oncology
@JCO_ASCO @ASCO #mmsm
โก๏ธ ascopubs.org/doi/10.1200/JCOโฆ
Abdul Rafae retweeted
When programs reward numbers, trainees chase numbers.
When programs reward thinking, trainees become physicians.
๐ฅ๐ฒ๐๐ฒ๐ฎ๐ฟ๐ฐ๐ต ๐ณ๐ผ๐ฟ ๐๐ต๐ฒ ๐๐ฎ๐ธ๐ฒ ๐ผ๐ณ ๐ฅ๐ฒ๐๐ฒ๐ฎ๐ฟ๐ฐ๐ต:
The article highlights how academic medicine is drifting toward an โabstract factoryโ model, where researchers, trainees, and institutions prioritize producing large numbers of abstracts and publications over meaningful, high-quality scholarship.
๐ช๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐ ๐๐๐ ๐๐๐๐ ๐ ๐๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐ ๐๐ ๐๐๐๐๐๐๐๐๐๐๐, ๐๐๐ ๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐๐ ๐๐๐๐ ๐๐๐๐๐๐๐๐
๐๐๐ ๐๐๐๐๐. ๐ป๐๐๐ โ๐๐๐๐๐๐๐ ๐๐๐๐โ ๐
๐๐๐๐๐๐๐ ๐๐๐๐๐
๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐๐, ๐
๐๐๐๐
๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐ ๐๐๐๐ ๐๐๐๐๐ ๐๐๐ ๐๐๐๐๐๐-๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐, ๐๐๐
๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐ ๐๐ ๐๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐ ๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐, ๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐ ๐๐๐๐ ๐๐ ๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐๐.
This pressure driven culture encourages superficial research, dilutes scientific rigor, and shifts focus away from curiosity, critical thinking, and true knowledge advancement.
The authors warn that this trend negatively impacts medical education, mentorship, and the integrity of science, and they call for a cultural reset that values depth, originality, and real clinical or scientific impact over sheer volume.
jamanetwork.com/journals/jamโฆ
Abdul Rafae retweeted
This slide perfectly illustrates the paradox of modern HR+ metastatic breast cancer management.
On paper, the postโCDK4/6 landscape is elegant and biologically rational: NGS-guided decisions, ESR1-targeted oral SERDs, PI3K/AKT pathway inhibitors, PARP inhibitors, and even CDK4/6 continuation strategies. Almost every resistance mechanism has a proposed solution.
In real life, howeverโin many countries, including my ownโmost of these red-highlighted options are simply not accessible. The algorithm exists, the evidence exists, the biomarkers existโฆ but the treatments do not.
So the question is unavoidable: who is this progress really for?
If we cannot deliver these drugs to patients, daily discussions about ever-expanding therapeutic menus risk becoming purely theoretical exercises.
Theoretical knowledge alone is not enough; translating it into practice is essential, but this is unfortunately not in the hands of physicians. It is a global problem.
So, where were we? What were we supposed to give patients with ESR1 mutations, those with PIK3CA alterations, and those with co-mutations? And then the questions keep coming: what if the DFI is less than 12 months? If ctDNA turns positive before radiologic progressionโwas that SERENA-6 or PADA-1?
After every conference, I find myself trapped in this paradox. Hopefully, one day everyone will have fair access to the treatments they deserve. Wishing you a nice weekendโit was a good conference. #SABCS25
Abdul Rafae retweeted
Management of Cancer During Pregnancy: ASCO Guideline
It is a remarkably comprehensive guide that addresses every question thoroughly๐
ascopubs.org/doi/10.1200/JCOโฆ
Abdul Rafae retweeted
In 2025, many important and long-awaited studies were published. I included them but kept the algorithms unchanged, as there are open questions about how these data will impact practice, particularly in early and metastatic HER2+ disease and mTNBC.
@DFCI_BreastOnc #SABCS25
Abdul Rafae retweeted
Highlights from #ASH25 #CommunityOnc:
#Lymphoma
1. #EPCOREFL1 FL
2. #CLL17 CLL
3. #BRUIN313/314 CLL
4. #S1826 HL
#Myeloma
5. #COBRA
6. #MajesTEC3
7. #AQUILA
8. #RedirecTT1
#Leukemia
9. #PARADIGM
@ASH_hematology #lymsm #mmsm #HemeTwitter 1/10
Abdul Rafae retweeted
Itโs time for #ASH25! Here is a๐ of ๐studies from #CommunityOncologists perspective.
- #BRUINCLL313
- #WINDOW3
- #ALPINE
- #MajesTEC3
- #MRD in Myeloma
- #COBRA
- #AUGMENT101
- #GimemaALL2820
- #VAYHIT2
- #VERIFY
#mmsm #lymsm #leuksm #HemeTwitter @ASH_hematology
Abdul Rafae retweeted
Replying to @allisonoconn
Iโm gonna put out there that we truly have no ideas how ADCs workโฆpmc.ncbi.nlm.nih.gov/articleโฆ
Abdul Rafae retweeted
BCMA-Based Therapies in Multiple Myeloma #mmsm
Summary of the approved drugs/combinations targeting BCMA with details on approval date, lines of therapy, supportive studies, common AEs as well as need for REMS
Updated 10/2025
Abdul Rafae retweeted
Wow.
All the benefit of checkpoint inhibition in A-BRAVE (high-risk TNBC) was seen in patients with TILs โฅ 30%. No benefit with low TILs.
Unbelievable that we didnโt get to see the TILs data from KN522 yet. Hope weโll see them soon.
Congrats @vitti10! #ESMO25 #ESMOAmbassadors
Abdul Rafae retweeted
The bar is raised! Periop ๐ฅช EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302*
โ
pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop
โ
2yr EFS & OS on par w DDMVAC in cis eligible
-cis eligible EVP๐ฅช trial *KNB15/EV304* readout awaited #ESMO25 โ at Berlin, Germany
Abdul Rafae retweeted
Important data from monarchE and NATALEE adjuvant CDK46 inhibitor @myESMO
With @tess_omeara, here's our take on who needs, and who does not need, adjuvant abema/ribo, co-published in @Annals_Oncology
annalsofoncology.org/articleโฆ
Abdul Rafae retweeted
๐จ #ESMO25 | ASCENT-03 (LBA20)
๐งฌ Sacituzumab Govitecan (SG) vs physicianโs-choice chemo in 1L PD-L1-negative or IO-ineligible mTNBC
Results (n = 558; median FU 13.2 mo):
Median PFS: 9.7 mo vs 6.9 mo โ HR 0.62 (0.50-0.78), p < 0.0001 โ
ORR: 48.4 % vs 45.5 %
Median DOR: 12.2 mo vs 7.2 mo
OS: immature
Safety:
G3+ AEs โ 66 % vs 62 %
Neutropenia 43 % / 41 %, diarrhea 9 %, anemia 16 %
Tx discontinuation 4 % vs 12 % โ better tolerability
๐ Interpretation:
SG delivers a clinically meaningful PFS gain (~3 mo) and more durable responses, with manageable toxicity.
๐ก Context:
Comparable PFS to KEYNOTE-355 (IO + chemo โ 9.7 mo), showing ADC monotherapy can rival IO + chemo in PD-L1โnegative or IO-ineligible mTNBC.
Looking forward to discussion on esmo day 3
#ESMO25 @myESMO
@OncoAlert
Abdul Rafae retweeted
One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases, anticipating the expansion of T-DXd to the curative setting, two Trop2 ADCs reaching first-line mTNBC, 2 novel ET-based combos, adjuvant CDK4/6i improving OS. See you in Berlin! #ESMOAmbassadors
Abdul Rafae retweeted
~2 wks to #ESMO25! Hereโs a๐of๐studies for GeneralOnc that could change/reinforce SoC:
- #DESTINYBreast 05&11
- #monarchE & #NATALEE
- #VIKTORIA1
- #FORTITUDE01
- #DYNAMIC3
- #STELLAR303
- #KN905
- #IMVigor011
- #PSMAddition
- #MDTBridge
#OncTwitter @myESMO @OncoAlert
Abdul Rafae retweeted
๐ฃDurva-FLOT was added to NCCN guidelines of gastric and GEJ adenoca
โ
For PDL1 positive tumors, category 1
โ
CPS or TAP
โ
PDL1 testing is recommended universal, not just for advanced disease
#cancer #oncology #MedX #gastric @OncoAlert @ASCO @myESMO @brunolarvol @SuyogCancer















































